|| carrier of a silent polymorphism in CYP3A5
|| CYP3A5*6 homozygote; nonexpressor for CYP3A5
|?|| (C;C) (C;T) (T;T) ||28|
, also known as 14690G>A, is a SNP in the CYP3A5
[PMID 21806386] indicates that this corresponds with CYP3A5*6, however, this seems doubtful. CYP3A5 allele nomenclature found at http://www.cypalleles.ki.se/cyp3a5.htm indicates that CYP3A5*6 (also known as 14690G>A) is a splicing defect resulting in essentially no activity in the gene. This does not correspond with dbSNP, which indicates that is a nucleotide substition (624G-A) which only results in a "silent" substitution of AAG (Lysine) to AAA (Lysine).
[PMID 21806386] Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients
[PMID 18341681] Graft rejection: pharmacogenetic analysis or drug anamnesis?
[PMID 18825162] Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.
[PMID 20354687] Explaining variability in ciclosporin exposure in adult kidney transplant recipients.
[PMID 20459744] Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.
[PMID 24427273] Global Pharmacogenomics: Distribution of CYP3A5 Polymorphisms and Phenotypes in the Brazilian Population
[PMID 23133420] Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin.